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Impaired insulin secretion contributes to the patho-
genesisof type2diabetesmellitus (T2DM). Treatment
with the incretin hormone glucagon-like peptide-1
(GLP-1) potentiates insulin secretion and improves
metabolic control in humans with T2DM. GLP-1
receptor-mediated signaling leading to insulin secre-
tion occurs via cyclic AMP stimulated protein kinase
A (PKA)- as well as guanine nucleotide exchange
factor-mediated pathways. However, how these two
pathways integrate and coordinate insulin secretion
remains poorly understood. Here we show that these
incretin-stimulated pathways converge at the level of
snapin, and that PKA-dependent phosphorylation of
snapin increases interaction among insulin secretory
vesicle-associated proteins, thereby potentiating
glucose-stimulated insulin secretion (GSIS). In dia-
betic islets with impaired GSIS, snapin phosphoryla-
tion is reduced, and expression of a snapin mutant,
whichmimics site-specific phosphorylation, restores
GSIS. Thus, snapin is a critical node in GSIS regula-
tion and provides a potential therapeutic target to
improve b cell function in T2DM.
INTRODUCTION
Insufficient glucose-stimulated insulin secretion (GSIS) signifi-
cantly contributes toward hyperglycemia in type 2 diabetes mel-
litus (T2DM) (Prentki and Nolan, 2006). Insulin is stored in secre-
tory vesicles in pancreatic b cells and is secreted by exocytosis
to precisely control blood glucose homeostasis (Gauthier and
Wollheim, 2008; Lang, 1999). Upon stimulus by glucose, b cells
secrete insulin in a biphasic manner, which is considered to be
important for optimal glycemic control (Del Prato and Tiengo,
2001; Pimenta et al., 1995). An early, first-phase insulin release
occurs during the first few minutes of glucose stimulus, whereas
later time points comprise the second phase of GSIS. Humans at
risk of developing T2DMor with established T2DMexhibit defec-
tive first-phase insulin release well before detectable changes in308 Cell Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc.the second phase (Gerich, 2002; Lillioja et al., 1988; Vaag et al.,
1995; Ward et al., 1984), and restoration of first-phase insulin
secretion corrects glycemic control (Basu et al., 1996).
The incretin hormone glucagon-like peptide-1 (GLP-1) and its
peptide analog exendin-4 (E4) improve metabolic control in
T2DM predominantly by restoring first-phase and augmenting
second-phase insulin secretion in humans with T2DM (Egan
et al., 2002; Fehse et al., 2005). In addition to their secretagogue
effects,GLP-1andE4stimulateproliferationand inhibit apoptosis
in rodent b cells (Drucker, 2006). Most if not all effects of GLP-1
and E4 in b cells appear to require intracellular activation of the
adenosine-30-50-cyclic monophosphate (cAMP) protein kinase A
(PKA) signaling pathway by the G protein-coupled receptor of
GLP-1, which is highly expressed on pancreatic b cells (Drucker
and Nauck, 2006). A secondmechanism of PKA-independent in-
cretin potentiation of GSIS involves the cAMP-regulated guanine
nucleotide exchange factor (cAMP-GEF) EPAC2 (Seino and Shi-
basaki, 2005). However, PKA activity appears to be essential for
optimal incretin effects on stimulating insulin vesicle exocytosis
(Chepurny et al., 2010; Doyle and Egan, 2007).
In b cells, insulin exocytosis is regulated in part by specific
kinases, which by altering protein phosphorylation modify
assembly of proteins associated to secretory vesicles (Foster
et al., 1998; Kwan et al., 2006; Shimazaki et al., 1996). Appro-
priate assembly of vesicle-associated proteins prepares the
secretory vesicle for exocytosis. In b cells, glucose metabo-
lism-inducedCa2+ elevation is required for the final stepof vesicle
fusion to the cell membrane (Gauthier and Wollheim, 2008;
Takahashi et al., 2010). While PKA signaling serves a central
role in incretin GSIS potentiation (Kwan et al., 2006; Seino and
Shibasaki, 2005), howPKA-dependent and -independent effects
of cAMP signaling are coordinated and integrated is unclear.
The node at which these two pathways converge, a protein likely
to be the target of PKA-dependent phosphorylation and to partic-
ipate in insulin vesicle exocytosis regulation, remains to be
identified.
To examine specifically in vivo effects of PKA signaling in
pancreatic b cells and to identify a PKA target protein important
in mediating coordinated incretin effects on GSIS, we have
generated a mouse model of disinhibited PKA activity by condi-
tional ablation of the inhibitory PKA regulatory subunit 1A
(prkar 1a). This mouse exhibits augmented GSIS and improved
glucose tolerance in the absence of fasting hyperinsulinemia
Figure 1. Prkar 1a Ablation in Pancreatic Islets
Immunoblot (left) with densitometric analysis (right, mean + SEM) of total islet protein fromWT-prkar 1a, het-prkar 1a, D-prkar 1a mice. Specific Prkar1a ablation
is detectable, while other prkar subtypes and Pkac remain unchanged. Prkar1a expression is approximately 50% reduced in het-prkar 1a islets and 90% reduced
in D-prkar 1a islets. CREB phosphorylation increases with reduced Prkar1a abundance.
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further find that humans that carry inactivating mutations in the
PKAR1A-encoding gene also exhibit augmented insulin secre-
tion and more rapid glucose disposal in response to an oral
glucose load, indicating a transspecies preservation of the
central regulatory role of PRKAR1A in b cell insulin secretion.
Here we show that PKA mediates incretin action on GSIS and
insulin exocytosis via phosphorylation of snapin, an exocytosis-
modulating protein initially identified in neuronal synapses
(Chheda et al., 2001; Ilardi et al., 1999). Snapin phosphorylation
is required for its interaction with protein components of the
insulin vesicle exocytosis apparatus and for integrating non
PKA-dependent incretin effects on insulin secretion (Seino and
Shibasaki, 2005). Expression in islets of a mutant snapin (S50D),
mimicking site-specific phosphorylation, reproduces incretin
effects in b cells, including the restoration of first-phase GSIS in
islets of diabetic mice.
Our findings indicate that snapin is a critical mediator of PKA-
dependent amplificationof glucose-stimulated insulin exocytosis,
and suggest its potential as a therapeutic target in strategies to
improve b cell function in diabetes mellitus.
RESULTS
Disinhibited PKA Activity in b Cells Augments
Glucose-Stimulated Insulin Secretion
Mouse Model of Prkar1a Ablation and Disinhibited
PKA Activity in Pancreas
To examine specifically the role of PKA in b cells without partic-
ipation of cAMP-stimulated PKA-independent (cAMP-GEF)
pathways, we generated a mouse model with tissue-specific
disinhibition of PKA activity. The PKA holoenzyme is composed
of a heterotetramer consisting of two PKA catalytic subunits
(Pkac) bound to two PKA regulatory subunits (Prkar). Once
generated through ligand G protein coupled receptor activationCeof adenylate-cyclase, cellular cyclic AMP binds Prkar, thereby
releasing and activating the Pkac.
Prkar1a, the most abundant regulatory subtype in b cells (Pe-
tyuk et al., 2008), was conditionally ablated using the CRE/LoxP
method by interbreeding floxed prkar 1a (prkar 1afl/fl) (Kirschner
et al., 2005) and pancreas-specific Pdx1-CRE mice (Lammert
et al., 2001). Offspring from such breeding carried all expected
genotypes at Mendelian frequency. Pdx1-CRE null/prkar 1afl/fl
(WT) served as control animals. The body weights of littermates
with different genotypes did not vary during an observation
period of up to 16 weeks (data not shown). Immunoblots of islet
extracts from Pdx1-CRE+/prkar 1afl/fl (D-prkar 1a), as compared
to controls, revealed a 90% reduction in Prkar1a protein, while
other Prkar isoforms and Pkac levels remained unaltered (Fig-
ure 1). D-prkar 1a mice exhibited increased islet PKA catalytic
activity, as reflected by elevated phosphorylation at serine 133
of Creb (cyclic AMP response element binding protein), an es-
tablished Pkac target (Gonzalez and Montminy, 1989) (Figure 1).
Islets with heterozygous prkar 1a ablation (het-prkar 1a) showed
the expected 50% reduction in Prkar1a protein (Figure 1).
Prkar1a Ablation Does Not Alter b Cell Proliferation
or Mass
In 8- to 9-week-old het-/D-prkar 1a and control littermates, islet
size or b cell mass was similar, as also were proliferationmarkers
Ki67 and EdU incorporation in b cells. Insulin content was not
different between D-prkar 1a and control islets (see Table S1
available online). The exocrine pancreas was unaltered in D-prkar
1a mice (data not shown). These results indicate that disinhibition
of PKA catalytic activity in pancreatic islets does not change b cell
mass or insulin content.
D-prkar 1a Mice Have Improved Glucose Tolerance
and Glucose-Stimulated Insulin Secretion
At 8–9 weeks of age, fasting glucose levels in het-/D-prkar 1a
mice were slightly and not significantly reduced when compared
to controls (Figure 2A). Prolonged observation up to 20 weeks ofll Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc. 309
Figure 2. Glucose-Stimulated Insulin
Secretion in D-prkar 1a, het-prkar 1a, and
WT-prkar 1a Mice In Vivo and from Respec-
tive Mouse Islets In Vitro
(A) Plasma glucose levels during an ipGTT in litter-
mates of indicated genotypes. D-prkar 1a mice
have markedly diminished glucose excursion
during ipGTT but do not exhibit baseline or post-
glucose hypoglycemia (*p < 0.05).
(B) Plasma glucose levels during ipITT in litter-
mates of indicated genotypes. No difference is
seen in insulin sensitivity among the different
genotypes (*p < 0.05).
(C) Serum insulin levels during ipGTT in littermates
of indicated genotypes. All animals have similar
baseline insulin levels.D-prkar 1amice havemark-
edly increased glucose-stimulated insulin levels,
predominantly during the initial phases of ipGTT
(*p < 0.05).
(D) Plasma glucose levels during an oGTT in litter-
mates of indicated genotypes. Baseline glucose
levels are similar in all animals. D-prkar 1a and
het-prkar 1a mice, respectively, have marked
and graded reductions in glucose excursion
during oGTT. Neither exhibits baseline or postglu-
cose hypoglycemia (*, #p < 0.05 versus WT).
(E) Serum insulin levels during oGTT in littermates
of indicated genotypes. All animals have similar
baseline insulin levels. D-prkar 1a mice have
marked and graded increases in glucose stimu-
lated insulin levels (*, #p < 0.05 versus WT).
(F) In vitro static insulin secretion assay of islets
cultured in glucose (3 and 10 mM) without and
with E4 (10 nM)-stimulated insulin secretion (*p <
0.05). Accumulated insulin in supernatant was
normalized to insulin in corresponding islets and
provided in percent islet insulin content.
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Figure 3. Oral GTT after Overnight Fast in
Humans with Inactivating PRKAR1A Muta-
tions and Controls
(A) Subjects with a PRKAR1A mutation exhibit
normal fasting glucose levels but reduced glucose
excursion after an oral glucose load.
(B) In subjects with a PRKAR1A mutation, serum
insulin levels were not different at baseline, and
reached a higher peak with increased overall
insulin secretion.
(C) Table summarizing fasting glucose and insulin
levels as well as area under the glucose and insulin
curvesshown in (A) and (B) (mean+SEM, *p<0.05).
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glucose levels betweenD-prkar 1a and littermates with normal or
haploinsufficient prkar 1a complement (data not shown). In
contrast, during ipGTT, D-prkar 1a mice exhibited dramatically
reduced glucose excursions (Figure 2A, Table S2). Insulin toler-
ance tests revealed no differences in peripheral insulin sensitivity
between D-prkar 1a and controls (Figure 2B). D-prkar 1a mice
exhibited significantly higher serum insulin levels in response
to intraperitoneal glucose administration, while baseline insulin
levels were not significantly different (Figure 2C, Table S2). Iden-
tical findings were made with b cell-specific prkar 1a ablation
using RIP2-CRE mice (data not shown). These results indicate
that in D-prkar 1a mice, in vivo GSIS is augmented, while basal
glucose and insulin levels are unaffected. This finding is reminis-
cent of incretin-mediated effects on GSIS, albeit under condi-
tions of intraperitoneal glucose administration, which bypasses
intestinal incretin hormone secretion (Drucker, 2006). These
observations suggest that islet Pkac disinhibition mimics incretin
potentiation of GSIS.
Het-prkar 1a and D-prkar 1a islets showed a graded increase
in serine 133 Creb phosphorylation (Figure 1), indicating a func-
tional relationship between disinhibited Pkac activity and
amount of islet Prkar1a. We reasoned that Prkar1a may also
have a gene dose-related effect on incretin action in b cells.
During an oral glucose tolerance test (oGTT), which stimulates
intestinal incretin hormone secretion from intestinal L cells
(Drucker, 2006), het-prkar 1a and D-prkar 1a exhibited in an
inverse relationship to prkar 1a levels, a graded improvement
in glucose tolerance (Figure 2D, Table S2), and a graded increase
in GSIS (Figure 2E, Table S2). Taking advantage of the high
expression level on b cells of the GLP-1 receptor (Doyle andCell Metabolism 13, 308–3Egan, 2007; Drucker, 2006), we directly
tested incretin action on b cell GSIS
in vitro on isolated islets in static incuba-
tion. Het-prkar 1a islets secreted more
insulin in response to glucose (10 mM)
than WT islets. E4 further potentiated
insulin secretion from het-prkar 1a as
compared to WT islets (Figure 2F). In
addition, D-prkar 1a islets showed
maximal GSIS, whichwas not augmented
by E4. In contrast, insulin secretion at
baseline glucose levels (3 mM) was not
different among the three genotypesand was not influenced by E4 (Figure 2F). These results suggest
that gene dose of prkar 1a regulates Pkac function and, hence,
b cell response to incretin. Also, the results indicate that with
Pkac disinhibition in complete prkar 1a absence, GSIS is
maximal with no additive incretin effect by E4.
Humans with Inactivating PRKAR1A Mutations Exhibit
Increased Glucose-Stimulated Insulin Secretion
We next examined whether our observations of murine islet PKA
disinhibition are reflected in humans carrying inactivating muta-
tions in PRKAR1A. From archival National Institutes of Health
(NIH) data of oGTTs, we identified young (17–27 years old)
patients with inactivating PRKAR1A mutations (Kirschner et al.,
2000) without any confounding endocrine hypersecretion (see
Table S3 for patient characteristics). During oGTT, individuals
with inactivating PRKAR1Amutations, as compared to matched
controls, exhibited significantly higher serum insulin levels
combinedwithmore rapid glucose disposal (Figure 3), as also re-
flected, respectively, by areas under the (AUC) insulin and
glucose curves (Figure 3). Remarkably, these results resemble
oGTT in het-prkar 1a mice (Figures 2D–2F).
Taken together, these findings indicate that Prkar1a subunit
influences both mouse and human b cell function. Furthermore,
based on the studies in mouse islets (Figure 2F), it is reasonable
to conclude that with haploinsufficient prkar 1a complement,
increased GSIS during an oGTT is at least in part due to
increased b cell response to incretin action (Figure 2F).
D-prkar 1a b Cells Exhibit Altered Insulin Vesicle
Morphology and Location
As increased insulin secretion in D-prkar 1a mice is not due to
changes in b cell mass or insulin production (Figure 2, Table
S1), we reasoned that improved GSIS results from alterations19, March 2, 2011 ª2011 Elsevier Inc. 311
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D-prkar 1a b cells showed significantly more insulin vesicles
located along the plasma membrane adjacent to intraislet capil-
laries (Figures S2A–S2F). In these mice, insulin vesicles located
closer than 1 mm to the plasma membrane were larger in size,
while the dense core size within the vesicles containing immuno-
detectable insulin were not different from controls. (Figures
S2G–S2I). These findings suggest that in b cells, disinhibited
PKA signaling results in altered morphologic characteristics of
insulin vesicles, which may possibly influence GSIS.PKA-Dependent Snapin Phosphorylation Increases
GSIS
PKA Mediates Snapin Phosphorylation at Serine
50 in b Cells
The morphological changes in insulin vesicles in D-prkar 1a
b cells prompted us to investigate candidate PKA phosphoryla-
tion targets associated with secretory vesicle exocytosis. PKA-
dependent snapin phosphorylation modulates vesicle exocy-
tosis in neuronal synapses by direct interaction with the soluble
N-ethylmaleimide-sensitive factor attachment protein receptor
(SNARE) complex protein SNAP-25 (Ilardi et al., 1999). Snapin
is also implicated in calcium-triggered vesicle fusion by regu-
lating the association between the SNARE complex and the
Ca2+ sensor synaptotagmin (Ilardi et al., 1999). In b cells, snapin
interacts with SNAP-25 and collectrin, a protein involved in regu-
lating insulin secretion and a transcriptional target of thematurity
onset of diabetes in the young (MODY) 3geneHNF1b (Fukui et al.,
2005).We confirmed the presence of snapin protein in pancreatic
b cell lines andmouse islets (Fukui et al., 2005) (Figure 4A). Immu-
nohistochemical analysis of mouse pancreas showed snapin co-
localization with insulin (Figure 4B), indicating high expression
levels of snapin protein in b cells. Despite reports that snapin
is expressed ubiquitously (Buxton et al., 2003), we did not find
snapin immunoreactivity in exocrine tissue.
Mouse (Figure 4C) and human (Figure 4D) islets exposed to E4
(10 nM), followed by snapin-specific immunoprecipitation (IP)
and immunoblot (IB) for phosphoserine, revealed E4 induced
snapin phosphorylation, whichwas inhibited by the PKA-specific
inhibitor myr-PKI (myristolated PKA inhibitor) (Figures 4C and
4D) and also by the cAMP antagonist Rp-8-CPT-cAMPs, which
blocks PKA activation (Figure S3A). Conversely, increased sna-
pin serine phosphorylation was found in D-prkar 1a islets as
compared to controls (Figure 4E).
Snapin amino acid sequence in mouse and human are >95%
identical with a PKA target phosphorylation site flanking serine
50 (Chheda et al., 2001). To verify the snapin phosphorylation
site at serine 50, we transiently expressed C-terminal flag-
tagged wild-type (WT), serine 50 to alanine (S50A), and serine
50 to aspartate (S50D) mutant human snapin isoforms in rat
insulinoma INS1 832/13 cells (Hohmeier et al., 2000) (Figure 5A).
Cells were treated with E4 with and without the PKA inhibitor
myr-PKI. In addition, in separate studies to verify whether
PKA mediates snapin phosphorylation, we also cotransfected
Pkac expression vector with the snapinWT andmutant isoforms.
FLAG-specific IP followedbyphosphoserine-specific IBconfirmed
serine phosphorylation of WT snapin, which was absent in S50A
and S50D mutants (Figure 5A).312 Cell Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc.These results indicate that snapin serine phosphorylation is
stimulated by incretin analog E4 via PKA signaling in both mouse
and human islets. Further, the results indicate that within the
snapin protein serine 50 is the sole PKA target serine phosphor-
ylation site.
Snapin Phosphorylation Increases Interaction
with Insulin Exocytosis Machinery Proteins
We next examined the relation of serine 50 phosphorylation to
snapin interaction with SNAP-25, collectrin and EPAC2. Coim-
munoprecipitation (IP/IB) studies with FLAG-tagged expression
of WT and mutant human snapin isoforms combined with E4
stimulation showed increased WT snapin interaction with
SNAP-25, collectrin, and EPAC2 (Figure 5A). This interaction
was absent with the S50A snapin mutant, which lacks the
PKA-dependent phosphorylation site (Fukui et al., 2005; Ilardi
et al., 1999). Conversely, snapin S50D, which mimics S50 phos-
phorylation, showed binding of snapin with SNAP-25, collectrin,
and EPAC2 even in the absence of PKA stimulation by E4 (Fig-
ure 5A). Stimulation of the PKA-independent pathway with the
EPAC-selective activator 8-pCPT-20-O-Me-cAMP-AM (10 mM)
increased SNAP-25-EPAC2 interaction but failed to stimulate
snapin-EPAC2 interaction (Figure S4). Taken together, these
results suggest that snapin phosphorylation is required for
robust interaction between snapin, SNAP25, and EPAC2, and
that phosphorylated snapin represents a node where incretin-
stimulated cAMP-PKA and cAMP-GEF pathways converge.
Vesicle exocytosis requires interaction of plasma membrane-
bound proteins (i.e., SNAP-25) with proteins bound to the secre-
tory vesicle proper (i.e., synaptotagmin, VAMP2). This protein
interaction leading to exocytosis is stimulated by a rise in
intracellular Ca2+, which in b cells occurs as a consequence of
a rise in glucose and glucosemetabolism (Gauthier andWollheim,
2008). To assess whether snapin phosphorylation affects interac-
tionamongplasmamembrane-bound (i.e., SNAP-25)with vesicle-
bound (i.e., VAMP2) proteins of the SNARE complex secretory
machinery,weexposed INS832/13cells expressingFLAG-tagged
snapin isoforms to low (3mM) and high (10mM) glucose levels for
30min followed by FLAG-specific coimmunoprecipitation studies
(IP/IB) (Figure 5B). The snapin S50D mutant coimmunoprecipi-
tated SNAP-25, collectrin, and EPAC2 in both low and high
glucose conditions. However, snapin-VAMP2 interaction was
detectable only at elevated (10 mM) glucose (Figure 5B). SNAP-
25-VAMP2 interaction was detectable only at 10 mM glucose in
presence of snapin S50D expression, suggesting that snapin
phosphorylation is permissive for SNAP-25-VAMP2 interaction.
This finding is consistent with a mechanism involving glucose-
dependent interaction of the insulin vesicle proteins with partner
plasma membrane proteins, which then leads to the final step of
exocytosis (Gauthier andWollheim, 2008; Takahashi et al., 2010).
Consistent with observations in insulinoma cells, coIP/IB
studies in primary cultured mouse islets exposed to E4 at low
(3 mM) and high (10 mM) glucose levels showed snapin interac-
tion in a PKA-dependent manner with SNARE complex protein
SNAP-25, as well as with collectrin and EPAC2 (Figure 5C).
Glucose stimulation (10 mM) did not further increase snapin
phosphorylation or snapin interaction with either SNAP25 or
EPAC2 above baseline levels. Interaction of both snapin and
SNAP-25 with VAMP2 was increased with E4 stimulation under
high (10 mM), but not low (3 mM) glucose culture conditions
Figure 4. Snapin Is Present in Insulinoma Cells and in Mouse and Human Islets
E4 stimulates snapin serine-phosphorylation in a PKA-dependent manner.
(A) Immunoblot for snapin, SNAP-25, collectrin, EPAC2, VAMP2, and actin in (1) control mouse brain, (2) H4IIE (rat hepatoma) cells, (3) 3T3-L1 cells, (4) INS1 832/
13 (rat insulinoma) cells, (5) MIN6 (mouse insulinoma) cells, (6) mouse islet protein extracts. Insulinoma cells and mouse islets express the proteins examined.
Hepatoma cells express EPAC2 only, 3T3-L1 cells do not express the examined vesicle-associated proteins.
(B) Immunohistochemical staining of mouse pancreas sections. Coimmunostaining with insulin (green) and with nonspecific antibody (top) or snapin-specific
antibody (bottom) (red). Nuclear counterstain with DAPI (blue). Separate pseudocolored images are shown with digitally merged image on bottom right panel,
respectively. Snapin immunoreactivity colocalizes with insulin immunoreactivity in pancreatic islets.
(C) Coimmunoprecipitation for snapin serine phosphorylation in mouse islets treated with E4 without or with PKA-specific inhibition with myr-PKI. E4 stimulates
snapin phosphorylation, which is inhibited by adding myr-PKI. Immunoblot for 10% of protein input at bottom.
(D) Coimmunoprecipitation for snapin serine phosphorylation in human islets treated with E4 (10 nM) without or with PKA-specific inhibition with myr-PKI. E4
stimulates snapin phosphorylation, which is inhibited by adding myr-PKI. Immunoblot for 10% of protein input at bottom.
(E) Snapin serine phosphorylation is increased in islets of D-prkar 1a mice. Coimmunoprecipitation for snapin serine phosphorylation in WT-prkar 1a and D-prkar
1a islets (bar graph: mean + SEM).
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action with SNAP25, collectrin, and EPAC2, indicating that sna-
pin interaction with these proteins requires PKA stimulation (Fig-
ure 5C). In accordance with these observations, D-pkar1a islets
showed increased snapin serine phosphorylation and increased
interaction between snapin and SNAP-25, collectrin, and EPAC2
(Figure 5C). Further, D-pkar1a islets also exhibited snapin-
VAMP2 interaction in the presence of high (10 mM) but not low
(3 mM) glucose levels (Figure 5D).CePhosphorylation at Residue 50 of Snapin Amplifies GSIS
To determine the importance of snapin phosphorylation on
GSIS, we conducted perifusion studies with mouse islets treated
with E4 or adenovirus-mediated overexpression of snapin S50D,
which specifically mimics snapin S50 phosphorylation. As ex-
pected, E4 treatment did not alter insulin secretion at low
(3 mM) glucose levels, but augmented both first and second
phases of insulin secretion at high (10 mM) glucose levels (Fig-
ure 5E). Treatment with the cAMP antagonist Rp-8CPT-cAMPsll Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc. 313
Figure 5. PKA-Mediated Phosphorylation of Snapin Maps to Serine 50
Snapin S50 phosphorylation increases interaction with secretory vesicle-associated proteins SNAP-25, EPAC2, and collectrin. Snapin interaction with VAMP2 is
glucose dependent. E4-stimulated SNAP-25 interaction with EPAC2 is not PKA mediated. Overexpression in islets of snapin S50D potentiates GSIS.
(A) Transiently transfected INS1 832/13 cells expressing C-terminal FLAG-tagged WT, S50A, or S50D snapin were treated with PBS (vehicle) E4 (10 nM), or
treated E4+myr-PKI, or transfected with Pkac followed by IP for FLAG or SNAP-25 and IB for phosphoserine or interacting proteins. Snapin serine phosphory-
lation occurs in WT snapin and not in S50A and S50Dmutants by E4 and Pkac action. E4 effect is inhibited by myr-PKI. Snapin interaction with SNAP-25, collec-
trin, or EPAC2 occurs only with phosphorylatedWT snapin (by E4 or Pkac) or with snapin S50D, as does SNAP-25 interaction with collectrin. SNAP-25 interaction
with EPAC2 occurs with E4 in a PKA-independent manner and is not inhibited by myr-PKI.
(B) Transiently transfected INS1 832/13 cells expressing C-terminal FLAG-tagged WT, S50A, or S50D snapin cultured in low (3 mM) or high (10 mM) glucose and
coIP/IB as in (A). Snapin S50D mutant binds SNAP-25, collectrin, and EPAC2 in both low and high glucose. Snapin interaction with VAMP2 occurs at elevated
glucose levels only. SNAP-25- VAMP2 interaction occurs only with snapin S50D and at elevated glucose levels.
(C) Isolated C57Bl/6 mouse islets cultured in low (3 mM) or high (10 mM) glucose and treated with PBS, E4 (10 nM), myr-PKI (10 nM), and E4+myr-PKI followed by
coIP/IB as in (A). Snapin serine phosphorylation is stimulated by E4 in a PKA-dependent manner and increases snapin interaction with SNAP-25, collectrin, and
EPAC2 independently of glucose levels. Snapin-VAMP2 interaction is stimulated by E4 in a PKA-dependent manner only with high glucose. E4 stimulates
SNAP25-EPAC2 interaction in a glucose- and PKA-independent manner. SNAP-25-VAMP2 interaction is stimulated by E4 in a glucose and PKA-dependent
manner. PKA activity is verified by phosphorylation of CREB at serine 133 (p-CREB).
(D) Control and D-prkar 1a islets cultured in low (3 mM) or high glucose (10 mM). IP for snapin or SNAP-25 and IB for phosphoserine and interacting proteins.
Snapin phosphorylation and snapin interaction with SNAP-25, collectrin, and EPAC2 are increased in D-prkar 1a islets independently of glucose levels. Sna-
pin-VAMP2 and SNAP-25-VAMP2 interactions are stimulated by high glucose only.
(E) Perifusion studies of C57Bl/6mouse islets in low (3mM) followed by high (10mM) glucose concentrations. Islets were treatedwith either PBS (inverted triangle)
or E4 (10 nM) (upright triangle) during perifusion, or had been transduced with control (circle) or snapin S50D (square)-expressing adenovirus. Table below curve
summarizes AUC for first- and second-phase insulin secretion (*p < 0.05 versus vehicle).
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sion showed no detectable change in insulin secretion at low
(3 mM) glucose levels, while at high (10 mM) glucose levels, first-
and second-phase insulin secretion were amplified in a qualita-
tively similar manner as observed with E4 (Figure 5E).314 Cell Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc.Snapin Is Critical for Insulin Secretion
To evaluate whether snapin participates in regulation of insulin
secretion, we knocked down snapin using murine sequence-
specific shRNA lentivirus in cultured mouse islets. Knockdown
was specific as reflected on immunoblot by approximately
Figure 6. Snapin Knockdown in C57Bl/6 Mouse Islets Diminishes
Insulin Secretion
Isolated mouse islets were transduced with lentivirus expressing shRNA with
nonspecific and snapin-specific sequences.
(A) (Left) Representative immunoblot of islet extracts shows 80% reduction of
snapin protein 48 hr after viral transduction; SNAP25, collectrin, EPAC2, and
VAMP2 remain unchanged. (Right) Densitometric analysis of immunoblots
from three different studies.
(B) Insulin secretion in static culture conditions from isolated islets with
knocked down snapin. In islets with reduced snapin, insulin secretion is dimin-
ished both at low (3mM) and high (10mM) glucose levels. Additional E4 admin-
istration does not significantly stimulate insulin secretion at low (3 mM) or high
(10 mM) glucose conditions.
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VAMP2, and EPAC2 protein levels remained unchanged (Fig-
ure 6). Islets with knocked down snapin exhibited diminished
insulin secretion at both low and high glucose and no longer re-
sponded to E4 stimulation. Adenovirus mediated re-expression
of FLAG-tagged human snapin after murine-specific shRNA
knockdown rescuedGSIS frommouse islets,while re-expression
of humansnapinS50Amutant hadnosucheffect. Conversely, re-
expression of human snapin S50D after murine snapin knock-
down augmented GSIS (Figure S5). These observations indicate
that snapin is required for insulin secretion from b cells.
Snapin S50 Is Occupied by O-Linked
b-N-Acetylglucosamine in Diabetic Mouse Islets
In T2DM, dynamic insulin secretion is impaired predominantly
resulting from defects in insulin exocytosis (Prentki and Nolan,
2006). We examined whether changes in insulin secretory
proteins, especially in snapin, may underlie in part the b cell
secretion defect in T2DM. In a mouse model of diet-induced
obesity (DIO) and T2DM (DIO diabetes) (i.e., hyperglycemia
and inappropriately low serum insulin levels) (Prentki and Nolan,
2006) (Figure 7A). Islet snapin, SNAP-25, EPAC2, and VAMP2
levels were not different as compared to nondiabetic controls
(Figure 7B). Collectrin levels were elevated in DIO islets, consis-
tent with previous observations (Figure 7B) (Fukui et al., 2005).
Importantly, phosphorylated snapin was reduced in DIO diabetic
islets, which also showed reduction in SNAP25-snapin and
SNAP-25-collectrin interactions (Figure 7B). In DIO diabetic
and control islets, E4-stimulated cAMP production was similar,
excluding diminished cAMP generation as a mechanism under-
lying the reduction in phosphorylated snapin fraction (data not
shown).
Hyperglycemia and DM are associated with increased post-
translational protein modification with O-linked b-N-acetylglu-
cosamine residues (O-GlcNAcylation) in peripheral tissues as
well as in pancreatic islets (Copeland et al., 2008; Slawson
et al., 2010). Islet protein O-GlcNAcylation is associated with
reduced insulin secretion (Akimoto et al., 2007). Enzymes
regulating O-GlycNAcylation, O-GlcNAc transferase, and
O-GlcNAcase are expressed at high levels in pancreatic islets
(Copeland et al., 2008; Wang et al., 2010).
Based on these observations, we reasoned that impaired
snapin S50 phosphorylation in DIO islets may result from snapin
O-GlcNAcylation. Indeed, DIO islets showed higher serine
O-GlcNAcylation than control islets (Figure 7B). Furthermore,
overexpression of WT and mutant snapin (S50A and S50D) iso-
forms in DIO islets showed O-GlcNAcylation of WT snapin but
not S50A and S50D mutants. This result indicates that the
O-GlcNAcylation site in snapin maps to serine 50, which also
serves as the PKA target phosphorylation site (Figure 7C).
E4 therapy produces rapid and sustained improvement of
insulin secretion in humans with T2DM (Egan et al., 2002; Fehse
et al., 2005) and in mouse models of T2DM (Doyle and Egan,
2007). We examined whether rapid E4 effects are reflected by
changes in proteins involved in insulin secretion andwhether sna-
pin S50 O-GlcNAcylation versus phosphorylation is modified. In
freshly isolated DIO diabetic islets, E4 administration acutely
increasedsnapinphosphorylationaccompaniedbya rapid reduc-
tion in O-GlcNAcylated fraction of snapin (Figure 7D). Protein
modification at serine and threonine can alternate between phos-Cephorylation andO-GlcNAcylation (Wanget al., 2010), and addition
and removal of O-GlcNAc moieties cycle rapidly (Copeland
et al., 2008), consistent with the time course of snapin S50
O-GlcNAcylation being replaced by phosphorylation.
Taken together, these results indicate that in hyperglycemic
DIO diabetic islets, snapin S50 is O-GlcNAcylated at the
expense of being phosphorylated. Snapin S50 O-GlcNAcylation
impairs snapin interaction with the SNARE complex protein
SNAP-25 and thus impairs insulin secretion. Pharmacologic E4
treatment acutely leads to an increase in snapin S50 phosphor-
ylation, while the S50 O-GlcNAcylated fraction diminishes.
These results provide a basis for functional impairment in insulin
secretion in DIO diabetic islets, which, consistent with clinical
observations, can acutely be reversed with E4-mediated incretin
action (Egan et al., 2002; Fehse et al., 2005).
Snapin S50D Augments GSIS and Restores Insulin
Secretion in Diabetic Mouse Islets
First-phase insulin secretion is important in controlling postpran-
dial glycemia (Vaag et al., 1995). In humans with T2DM andll Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc. 315
Figure 7. Impaired GSIS in DIO Diabetic Mouse Islets Is Corrected with Snapin S50D
(A) Glucose and insulin levels of 12-week-old C57Bl/6 littermate mice on either normal diet and after 6 weeks of high-fat diet. Mice on high-fat diet are hypergly-
cemic and have relative insulin deficiency.
(B) Immunoblot of islet proteins from C57Bl/6 mice on normal chow and high-fat diet.
(C) Mapping of snapin serine-O-GlcNAcylation. DIO diabetic islets were transduced with adenovirus-expressing C-terminal FLAG-tagged WT, S50A, and S50D
snapin isoforms. Immunoprecipitation with FLAG antibody followed by immunoblot was performed. Representative immunoblot is shown.
(D) Time course of snapin phosphorylation after E4 treatment of cultured islets of diet-induced diabetic mice.
(E) Perifusion studies of DIOmouse islets in low (3 mM) followed by high (10 mM) glucose concentrations. Islets were treated with either PBS (inverted triangle) or
E4 (10 nM) (upright triangle) during perifusion, or had been transduced with control (circle) or snapin S50D (square)-expressing adenovirus. Table below curve
summarizes AUC for first- and second-phase insulin secretion (*p < 0.05 versus vehicle).
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ished and can be stimulated with incretin hormone both acutely
and during chronic treatment. We reasoned that in DIO islets,
expression of snapin S50D, which mimics snapin phosphoryla-
tion and is also impervious to O-GlcNAcylation, would affect
GSIS in a similar fashion as the incretin analog E4. In perifusion
studies, DIO diabetic islets exhibited diminished first-phase316 Cell Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc.and reduced second-phase insulin secretion, consistent with
previous observations (Peyot et al., 2010). In these islets, E4
treatment restored the absent first phase and increased second
phase of GSIS. Adenovirus-mediated snapin S50D overexpres-
sion in DIO diabetic islets similarly resulted in restoration of first-
phase and potentiation of second-phase insulin secretion (Fig-
ure 7E). Taken together, these results suggest that in DIO
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Snapin Phosphorylation Augments Insulin Secretiondiabetes mellitus, snapin S50 phosphorylation in large part
mediates incretin effects on GSIS amplification.
DISCUSSION
Thepresent studiesofageneticallydefinedmousemodel highlight
the predominant in vivo role of PKA signaling in potentiating b cell
GSIS, whereas disinhibition of islet PKA activity does not alter
b cell proliferation ormass. In addition, this model reveals Prkar1a
asa functionally important regulatoryPrkar subtype formouseand
human insulin secretion.Our studies identify PKA-mediatedphos-
pho-S50 snapin where cAMP-PKA and cAMP-GEF pathways
converge leading toward GSIS potentiation. In b cells, snapin
appears to have two related, but distinct roles: (1) snapin is critical
for insulin secretion, as revealed by snapin knockdown in islets
(Figure 6); and (2) snapin serves in b cells as the predominant
PKA target, which upon phosphorylation at serine 50 promotes
interaction and assembly of insulin secretory vesicle-associated
proteins SNAP-25, collectrin, and EPAC2 (Figure 5).
The studies of het-prkar 1a mice (Figures 2D–2F) are reflected
in our observations in humans with inactivating mutations in the
PRKAR1A gene, who have higher serum insulin excursions in
response to an oral glucose load, indicating higher insulin secre-
tion (Figure 3). In this regard, it will be interesting to examine
whether patients with mutations at the PRKAR1A locus are rela-
tively protected from b cell failure or diabetes mellitus. Impor-
tantly, patients with inactivating PRKAR1A mutations are not
known to develop islet cell tumors, suggesting that disinhibition
of PKA signaling in islets does not cause tumor formation as in
other endocrine tissues (Boikos and Stratakis, 2006).
A PKA-independent, cAMP-mediated potentiation of GSIS
involves cAMP-regulated GEF EPAC2. Our findings confirm that
PKA-independent incretin action promotes SNAP-25-EPAC2
interaction (Figure 5, Figure S1) (Kwan et al., 2006; Seino and Shi-
basaki, 2005). However, interaction of SNAP-25 and EPAC2 with
snapin requires PKA-dependent snapin phosphorylation.
Further, snapin is essential for b cell insulin secretion (Figure 6).
Thus, our findings suggest amodel in which phosphorylated sna-
pin serves as a node,wherePKA-independent (EPAC2) andPKA-
dependent (snapin phosphorylation) incretin effects converge,
resulting in increased interaction among proteinmembers impor-
tant for insulin vesicle exocytosis. While PKA appears to have
permissive effects on EPAC2 action (Chepurny et al., 2010), the
relative in vivo roles of EPAC2 and snapin in incretin potentiation
of GSIS remain unclear. Mouse islets lacking EPAC2 show
impaired cAMP analog potentiation of first-phase GSIS (Shiba-
saki et al., 2007), while first-phase GSIS also depends on PKA
action (Hatakeyama et al., 2006), indicating that first-phase
insulin secretion may be dually regulated by EPAC2 and PKA.
Since mice lacking snapin do not survive the postnatal period
(Tian et al., 2005), conditional b cell-specific models of EPAC2
and snapin ablation will be necessary to evaluate the in vivo roles
of these proteins on insulin secretion and incretin action.
Incretins augment insulin secretion only when glucose levels
are above a certain threshold beyond normoglycemia (Drucker,
2006). Consistent with this concept of glucose-dependent
potentiation of GSIS, patients with inactivating PRKAR1A muta-
tions as well as het-/D-prkar 1a mice do not have fasting hypo-
glycemia or hyperinsulinemia but exhibit augmented insulinCesecretion as glucose levels rise (Figures 2 and 3). Similarly, sna-
pin S50D overexpression in mouse islets results in potentiated
GSIS, while insulin secretion at low glucose levels is not
augmented (Figure 5E). These findings are consistent with the
existing model of regulated exocytosis in which proteins bound
to the inside surface of the cytoplasmic membrane, on one
hand, interact with proteins attached to the secretory vesicle,
on the other hand, through a ‘‘handshake’’ of coiled-coil motifs
on both sides (Sudhof and Rothman, 2009; Takahashi et al.,
2010). Snapin interacts with the plasma membrane proteins
(SNAP-25, collectrin) in a S50 phosphorylation-dependent
manner and promotes assembly of vesicle-associated proteins,
preparing the secretory vesicle for exocytosis. Finally, elevated
glucose levels promote snapin interaction with the vesicle-asso-
ciated protein VAMP2 (Figure 5).While the present studies do not
exclude PKA-dependent effects outside of snapin phosphoryla-
tion (Lester et al., 2001), the observations suggest that PKA-
dependent snapin S50 phosphorylation is an important intracel-
lular mediator of incretin onGSIS, while also permitting a glucose
dependency of insulin secretion (Hatakeyama et al., 2006).
Our studies provide a molecular basis for clinical observations
made during E4 administration in humans. Type 2 diabetic
subjects exhibit defective first-phase insulin release, and restora-
tion of first-phase insulin secretion is critical for optimal glycemic
control (Basu et al., 1996). Our studies indicate that incretin-
mediated snapin phosphorylation restores first-phase insulin
secretion and augments second-phase GSIS (Figure 7). In DIO
diabetic islets, alternate O-GlcNAcylation and phosphorylation
at snapin S50 provide amechanism for (1) impaired insulin secre-
tion in diabetic islets due to snapin O-GlcNAcylation, disturbing
snapin-SNAP-25 interaction; and (2) rapid incretin-mediated
replacement of snapin S50O-GlcNAcylation by phosphorylation,
allowing phosphosnapin interaction with SNAP-25 (Figures 7D
and 7E) and likely other protein members of the exocytosis
machinery, thereby enabling insulin secretion to proceed.
Our findings suggest that snapin S50 phosphorylation
provides unifying mechanistic underpinnings of the following
properties of incretin action: (1) glucose dependency in aug-
menting insulin secretion, (2) rapid action of GLP-1 and E4 in
stimulating first- and second-phase insulin secretion, and (3)
rapid effectiveness in DIO diabetic islets in restoring first- and
second-phase insulin secretion, by altering the proportion of
phosphorylated to O-GlcNAcylated snapin S50.
In a broader context, for efforts to ameliorate glycemic control
and increasing GSIS, both PRKAR1A and snapin are potential
drug targets in b cells for treating diabetes mellitus in humans.
EXPERIMENTAL PROCEDURES
Animal Studies
Prkar1afl/fl, RIP2-CRE, and Pdx-1-CRE mice were previously reported (Kirsch-
ner et al., 2005; Lammert et al., 2001; Lee et al., 2006) and were kept in amixed
genetic background (C57Bl/6 3 FVB). Animal studies were approved by the
institutional animal care and use committee at Johns Hopkins University,
where animals were housed in a dedicated vivarium. Dynamic physiologic
test details are provided in the Supplemental Information.
Immunofluorescence Histology and Islet Morphometry
Immunofluorescence histology and islet morphometry were conducted as
previously described (Hussain et al., 2006; Song et al., 2008). EdU incorpora-
tion (100 mg i.p. 3 5 days) was detected using Click-It (Invitrogen).ll Metabolism 13, 308–319, March 2, 2011 ª2011 Elsevier Inc. 317
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Standard protocols for transmission and immunoelectron microscopy were
used. See the Supplemental Information for details.
Isolated Islet Studies
Islets isolation, static insulin secretion, and perifusion tests were performed as
previously described (Chepurny et al., 2010; Hussain et al., 2006; Song et al.,
2008) and described in detail in the Supplemental Information. Islet insulin
(Alpco ELISA) content was determined after acid ethanol (0.18M HCl in 70%
ethanol) extraction (Hussain et al., 2006).
shRNA Knockdown Studies
Scrambled (random) and murine snapin-specific (TI526219 in pRS, Origene
Technologies) shRNA-expressing, purified (Virabind, Invitrogen) lentiviral parti-
cles (approximately 105 viral particles) were spinoculated (O’Doherty et al.,
2000) twice with freshly isolated islets in presence of polybrene (2 mg/ml,
Sigma). For re-expression of snapin isoforms after shRNA knockdown, adeno-
virus-expressing FLAG-tagged human snapin isoforms, which are not affected
by mouse-specific shRNA, were added within 24 hr after spinoculation and
initiation of shRNA knockdown. After a total of 3 days in culture, islet insulin
secretion assays were performed followed by protein and RNA extractions
for further analyses.
Protein Coimmunoprecipitation
Protein coimmunoprecipitation studies were performed using standard proto-
cols (Cell Signaling Technologies). Band intensity of interrogated protein was
normalized to the corresponding actin intensity (BioRad Chemidoc XRS).
Representative immunoblots are shown. Immunoblots (IBs) were performed
with at least three different separately obtained experimental samples.
Antibodies used are provided in Table S4.
Human Studies
Human subjects had provided informed consent under approved protocol by
the NIH institutional review board. oGTTs (75 gr glucose per os after an over-
night fast) were performed at the clinical research center of the NIH on subjects
carrying inactivating mutations of the prkar 1a gene verified by sequencing of
prkar 1a exons (Kirschner et al., 2000). Control subjects were selected to
match age as well as relevant medical history with patients carrying the prkar
1a mutation. Test data were archived at the NIH database until analysis.
Statistics
Results are shown as averages and standard errors of the mean (SEM). Where
appropriate, Student’s t test, nonparametric Mann-Whitney U test, or analysis
of variance (ANOVA) was used to calculate differences between groups. p <
0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article at doi:10.
1016/j.cmet.2011.02.002.
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